Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Summary of Evidence-Based Guideline Update: Evaluation and Management of Concussion in Sports
Neurol 80:2250-2257, Giza, C.,et al, 2013
Clinical Presentation of Chronic Traumatic Encephalopathy
Neurol 81:1122-1129, Stern, R.A.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Traumatic Brain Injury - Football, Warfare, and Long-Term Effects
NEJM 363:1293-1296, DeKosky,S.T.,et al, 2010
Cerebral Amyloid Angiopathy
UpToDate: May 2010, Greenberg,S.M.,et al, 2010
Amateur Boxing and Risk of Chronic Traumatic Brain Injury: Systematic Review of Observational Studies
BMJ 335:809-812,781, Loosemore,M.,et al, 2007
Course of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 68:1411-1416, Kinnecom,C.,et al, 2007
Clinical Manifestations of Cerebral Amyloid Angiopathy-Related Inflammation
Ann Neurol 55:250-256, Eng,J.A.,et al, 2004
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
APOE Genotype is a Major Predictor of Long-Term Progression of Disability in MS
Neurol 56:312-316, Chapman,J.,et al, 2001
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
Cerebral Amyloid Angiopathy:Propsects for Clinical Diagnosis and Treatment
Neurol 52:690-694, Greenberg,S.M., 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Corticobasal Degeneration:Neuropathologic and Clinical Heterogeneity
Neurol 48:959-969, Schneider,J.A.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Association of Apolipoprotein E Polymorphism with Outcome after Head Injury
Lancet 350:1069-1071, Teasdale,G.M.,et al, 1997
Clinicopath Conf
Cerebral Amyloid Angiopathy, Case 22-1996, NEJM 335:189-196996., , 1996
Apolipoprotein E and Cognitive Decline in Alzheimer's Disease
Neurol 47:317-320, Plassman,B.L.&Breitner,J.C.S., 1996
High Apolipoprotein E e4 Allele Frequency in Age-Related Memory Decline
Ann Neurol 39:548-551, Blesa,R.,et al, 1996
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Apolipoprotein E Genotyping in the Differential Diagnosis, Not Prediction, of Alzheimer's Disease
Ann Neurol 38:6-14, Roses,A.D., 1995
Apolipoprotein E Genotyping in the Diagnosis of Alzheimer's Disease:A Cautionary View
Ann Neurol 38:2-4, Bird,T.D., 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995